Comments
Laurus Labs Ltd has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market Covid-19 drug 2-Deoxy-D-Glucose (2DG).
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on Covid-19 patients in the country.
Laurus Labs has already applied with CDSCO for emergency use authorisation (EUA) for 2DG, according to a release.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.